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Abstract
Introduction The use of cultured cell lines as model systems for
normal tissue is limited by the molecular alterations
accompanying the immortalisation process, including changes
in the mRNA and microRNA (miRNA) repertoire. Therefore,
identification of cell lines with normal-like expression profiles is
of paramount importance in studies of normal gene regulation.
Methods The mRNA and miRNA expression profiles of several
breast cell lines of cancerous or normal origin were measured
using printed slide arrays, Luminex bead arrays, and real-time
reverse transcription-polymerase chain reaction.
Results We demonstrate that the mRNA expression profiles of
two breast cell lines are similar to that of normal breast tissue:
HB4a, immortalised normal breast epithelium, and PMC42, a
breast cancer cell line that retains progenitor pluripotency
allowing in-culture differentiation to both secretory and
myoepithelial fates. In contrast, only PMC42 exhibits a normal-
like miRNA expression profile. We identified a group of miRNAs
that are highly expressed in normal breast tissue and PMC42
but are lost in all other cancerous and normal-origin breast cell
lines and observed a similar loss in immortalised lymphoblastoid
cell lines compared with healthy uncultured B cells. Moreover,
like tumour suppressor genes, these miRNAs are lost in a variety
of tumours. We show that the mechanism leading to the loss of
these miRNAs in breast cancer cell lines has genomic,
transcriptional, and post-transcriptional components.
Conclusion We propose that, despite its neoplastic origin,
PMC42 is an excellent molecular model for normal breast
epithelium, providing a unique tool to study breast differentiation
and the function of key miRNAs that are typically lost in cancer.
Introduction
Despite its many shortcomings, continuous cell culture
remains the most common model system for investigating
molecular mechanisms of normal differentiation, disease, and
neoplastic transformation (reviewed in [1]). This is thanks
mostly to ease of use, homogeneity, availability in large quanti-
ties, and sustainability over prolonged periods of cell culture.
Cell lines typically are established either from tumours (primary
or metastatic) or from immortalised normal cells often used as
experimental models of healthy tissue. However, the normal
physiology of many cell types depends on their native neigh-
bouring cell types and extracellular matrix (ECM), exemplified
in the context of the breast by the dependence of luminal (epi-
thelial/secretory) cells on their basal (myoepithelial) neigh-
bours and surrounding ECM components for maintenance of
polarity and differentiation [2,3]. Thus, isolation of individual
cells for their propagation in culture often leads to partial loss
ATCC = American Type Culture Collection; BAC = bacterial artificial chromosome; BM = basement membrane; CGH = comparative genomic hybrid-
isation; ECM = extracellular matrix; EGF = epithelial growth factor; ER = oestrogen receptor; miRNA = microRNA; PAP = poly(A) polymerase; PBS 
= phosphate-buffered saline; PCR = polymerase chain reaction; PN miRNA = microRNA specifically expressed in PMC42 and Normal breast tissue; 
PR = progesterone receptor; qRT-PCR = quantitative reverse transcription-polymerase chain reaction; RT = reverse transcription; SSC = Saline 
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of normal phenotype. Moreover, both one-off major changes
incurred on the cell by the immortalisation process (be it natu-
ral or induced) and gradual drifts in karyotype, growth, and dif-
ferentiation characteristics affect all cell lines and do not spare
those with normal ancestry. Taken together, these limitations
raise the question of whether immortalised normal cells are
necessarily the optimal choice to represent healthy tissue, or
in other words, what underlies the 'normality' of the healthy tis-
sue and whether these features are maintained in culture. The
matter is by no means a new one. A review published 17 years
ago by Mina Bissell [4] summarised debates that at the time
surrounded morphological, metabolic, and protein expression
aspects of cell lines and their validity as representatives of nor-
mal tissue. Unfortunately, it appears that the progress of cell
and molecular biology has done little to relieve the controver-
sies since. Despite the ability to do genome-wide profiling and
the ever-expanding list of available 'tumour markers', we are
still unable to define what constitutes a good model system for
normal gene expression.
PMC42 is a breast carcinoma cell line established from a pleu-
ral effusion of a woman with metastatic breast cancer [5-7].
Despite bearing some hallmark features of other cancer cell
lines (namely, loss of contact inhibition and a highly rearranged
karyotype), PMC42 is remarkably similar to normal breast epi-
thelial tissue, suggesting that unlike most common breast can-
cer cell lines stemming from tumours of luminal or
myoepithelial/basal cells, PMC42 is a rare cell line originating
from a breast stem cell retaining much of the breast's native
phenotype. First, PMC42 exhibited stable heterogeneity of at
least eight morphologically distinct cell types arising from in-
culture differentiation of both epithelial and myoepithelial prog-
eny all the way to terminal differentiation and cell death. Sec-
ond, the cells were shown to respond to hormonal stimuli in a
manner similar to breast epithelial tissue, such as the appear-
ance of lipid droplets upon treatment with prolactin or stimula-
tion of growth by hydrocortisone, in marked contrast to other
breast tumour cell lines inhibited by this glucocorticoid [7].
Moreover, the cord-like subpopulation of PMC42 not only
responded to epithelial growth factor (EGF) stimulus but also
could attach to collagen and laminin matrices. EGF stimulation
of monolayer PMC42 induced morphological, biochemical,
and phenotypical changes reminiscent of epithelio-mesenchy-
mal transition in vivo [8]. Lastly, it was demonstrated that, by
exposing PMC42 grown on Matrigel-coated plates to a com-
bination of hormonal stimuli, the cells could be driven to form
hollow organoids expressing β-casein [9], thus fulfilling two
additional criteria commonly used for normal breast epithelial
differentiation.
Understanding stem cell self-renewal and cellular differentia-
tion is one of the current challenges in biomedical research.
The current paradigm considers both intrinsic (for example,
transcription factors) and extrinsic (for example, signalling
pathways) contributions to the balance between self-renewal
and differentiation (reviewed in [10]). In recent years, it has
become increasingly clear that post-transcriptional regulation
of gene expression by microRNAs (miRNAs) is a major intrin-
sic component in numerous systems, including neuronal differ-
entiation, the development of skeletal and cardiac muscle, and
the formation of the haematopoietic system (reviewed in [11-
13], respectively). Moreover, since their discovery in 1993,
miRNAs have rapidly secured an undisputed status as key
players in malignancy [14,15]. We therefore undertook to
examine the gene expression profiles underlying the normal-
like phenotype of PMC42 in contrast to other commonly used
breast cell lines (normal and cancer-derived).
Materials and methods
General comments
All oligonucleotide sequences are listed 5'-3' (uppercase =
DNA, lowercase = RNA, p = phosphate). Annotation of miR-
NAs varied slightly between platforms. Thus, where consid-
ered helpful, annotation was manually unified.
Cell culture and isolation of total RNA and small-RNA 
fractions
The following adherent cell lines were used for the core find-
ings of this work: oestrogen receptor/progesterone receptor
(ER/PR)-positive normal immortalised breast epithelium HB4a
(from the originator) [16], ER/PR-positive basal/progenitor
breast cancer PMC42 (from Michael O'Hare) [5], ER/PR-neg-
ative basal breast cancer BT-20 (from Michael O'Hare) [17],
ER/PR-negative luminal breast cancer HCC1419 (from Amer-
ican Type Culture Collection [ATCC], Manassas, VA, USA)
[18], ER/PR-positive breast cancer MCF7 (from ATCC) [19],
ER/PR-positive MDA-MB-361 (from ATCC) [20], and ER/PR-
negative MT-3 (from the originator [21], originally isolated as a
breast cancer line, later determined to be LS-174T, a colon
cell line [22]). All of the above cell lines have been previously
karyotyped [23,24].
For validation of miRNA expression, we have used the immor-
talised normal epithelial breast cell lines HMT-3522 [25] and
MCF-10A [26] (from ATCC) as well as the following breast
cancer cell lines (from Paul Edwards) ([24] and references
therein): T47-D, SUM190, OCUBF, MDA-MB-468, SK-BR-3,
SUM-52, SK-BR-7, HCC1187, CAMA-1, MDA-MB-231, and
HCC1937.
The ER and PR status of the cell lines was obtained from the
references above and from publicly available databases [27-
29]. Where available, the luminal/basal nature of the cell lines
was obtained from [30] and verified by quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) of
selected genes (data not shown). For ease of annotation,
hyphens have been omitted from the cell line names through-
out the rest of the manuscript.Available online http://breast-cancer-research.com/content/10/3/R54
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Cells were cultured according to suppliers' recommendations.
RNA was harvested from subconfluent cultures (estimated
85% density) that were re-fed with fresh medium 24 hours
prior to harvesting. In brief, cultures were washed once with
cold phosphate-buffered saline (PBS). Upon complete
removal of the PBS, cells were lysed directly in 8 mL of TRI
reagent (Sigma-Aldrich, St. Louis, MO, USA) and processed
according to manufacturer's protocol with the following modi-
fication: precipitation of RNA out of the aqueous phase was
performed overnight at -20°C in the presence of 1.7 volumes
of 2:1 ethanol/isopropanol and additional 0.3 M NaOAc (pH
5.5). Small RNAs were further purified using the miRVANA kit
(Ambion, Austin, TX, USA). The yield and quality of the small
RNAs were monitored by electrophoresis of approximately 1
μg of total RNA and the corresponding proportion of the small-
RNA fraction through a 15% acrylamide/urea vertical gel and
subsequent staining with 1:10,000 SYBR Gold (Molecular
Probes, now part of Invitrogen Corporation, Carlsbad, CA,
USA). Small-RNA fractions were extracted with a near 100%
efficiency, comprised 7% to 17% of the total RNA, and con-
tained predominantly tRNAs and small rRNA. No miRNA-sized
RNA was ever visible in miRVANA fractions from cell lines
(<0.5 ng). Total RNA from individual normal breast (from
Ambion and Stratagene [La Jolla, CA, USA], termed through-
out the paper as NormalA and NormalS, respectively) was sim-
ilarly processed for small-RNA fractions.
mRNA profiling on beadchip arrays
Total RNA was labelled using the Illumina TotalPrep RNA
Amplification kit (Ambion) in accordance with the manufac-
turer's instructions. Briefly, 200 ng of total RNA was reversed-
transcribed in a 20-μL reaction for 2 hours at 42°C. Second-
strand cDNA synthesis was performed at 16°C for 2 hours,
and the resulting double-stranded cDNA was purified and
washed using filter columns provided with the kit. Finally, the
cDNA was transcribed in vitro at 37°C for 14 hours using T7
RNA polymerase and a biotin-NTP mix. Upon completion, the
reaction was diluted with 75 μL of nuclease-free water and the
cRNA was purified and washed using filter columns to retrieve
a 100-μL eluate.
Biotin-labelled cRNA (1.5 μg) in 20 μL was used for each
hybridisation on Sentrix Human-6 BeadChips (Illumina, San
Diego, CA, USA) in accordance with manufacturer's protocol.
In brief, samples were mixed with 40-μL hybridisation mix (3:2
hybridisation buffer/deionised formamide) and preheated at
65°C for 5 minutes. The 60-μL assay sample was dispensed
onto the array immediately after cooling to room temperature
and incubated for 18 hours at 55°C. After the overnight incu-
bation, the slides were washed at 55°C followed by three
room temperature washes. Finally, the slides were blocked
and the cRNA was detected by a 10-minute incubation with
streptavidin-Cy3. After an additional wash at room tempera-
ture, the slides were spin-dried and scanned using the default
settings of the Illumina BeadArray reader (Illumina).
Illumina's BeadStudio software (version 1.5.1.3) was used to
process raw array data according to [31] and to output a sin-
gle summarised value for each of the 48,000 genes on each
array. These non-normalised data were then read into the Bio-
conductor bead array [31] software for quality control and nor-
malisation. Quality control checks showed low variability
between replicate arrays and no evidence of experimental bias
between arrays. The data were then normalised by scaling to
the global median or by quantile normalisation and are availa-
ble on ArrayExpress under accession number E-TABM-194
(temporary username: Reviewer_E-TABM-194, password:
1166801733027). An empirical Bayes analysis of variance
approach [32] was then used on the normalised data to sepa-
rate genes that were differentially expressed between samples
from genes with equal expression level across all samples. The
result was a list of B-statistics for each gene under the two
normalisation approaches, with a larger statistic indicating
greater evidence for differential expression. Genes with B-sta-
tistics of greater than 10 for either normalisation were then
selected for further analysis. Gene ontology analysis was per-
formed using the web-based FatiGo software [33,34].
The genes used for luminal/basal analysis in Figure 1b were
based on the recently reported luminal/basal gene set signa-
ture in breast cell lines (1,233 genes [30]), out of which we
selected 612 (252 luminal and 360 basal) genes for which a
unique gene symbol annotation was available in the original
study and for which only one probe was present in our bead-
chip array.
MicroRNA profiling on slide arrays
Individual small-RNA fractions or a pool containing equal
quantities of small-RNA fractions from the six cancer cell lines
was labelled with a Genisphere Array 900 miRNA RT kit
(MIRT180; Genisphere, Hatfield, PA, USA) in accordance
with manufacturer's instructions. Briefly, 500 ng of small-RNA
fraction was polyA-tailed for 15 minutes at 37°C using poly(A)
polymerase (PAP). The tailed samples were then reverse-tran-
scribed using Superscript II (Invitrogen Corporation) for 1 hour
at 42°C and one of two capture primers (Cy3-capture primer
TTCTCGTGTTCCGTTTGTACTCTAAGGTGGA-T17; Cy5-
capture primer ATTGCCTTGTAAGCGATGTGATTCTATT-
GGA-T17) spanning a capture sequence later to be detected
by complementary oligonucleotides tagged with approxi-
mately 850 fluorophor moieties each, included in the kit. Upon
completion, the two cDNAs (primed with either Cy3-capture
or Cy5-capture) were combined and concentrated with Micro-
con YM-50 columns (Millipore Corporation, Billerica, MA,
USA) to a final volume of 25 μL.
The profiling was performed on homemade arrays bearing 171
miRNA, 4 tRNA, and 3 snRNA amine-modified probes synthe-
sised in sense orientation by QIAGEN-Operon and spotted in
32 or 64 replicates on amine-reactive Codelink slides (GE
Healthcare, Little Chalfont, Buckinghamshire, UK). Prior to theBreast Cancer Research    Vol 10 No 3    Git et al.
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hybridisations, the slides were blocked in a 1% wt/vol ammo-
nium hydroxide solution for 5 minutes with gentle shaking,
rinsed in water, and spin-dried. Labelled samples were mixed
with 25 μL of MIRT180 hybridisation buffer and incubated at
80°C for 10 minutes and then at 37°C until loading onto a pre-
warmed array. After an overnight incubation at 37°C in a dark
humidified chamber, the slides were washed for 15 minutes at
42°C in pre-warmed 2× Saline Sodium Citrate (SSC), 0.2%
SDS buffer, 15 minutes in 2 × SSC at room temperature, and
15 minutes in 0.2 × SSC at room temperature and, finally,
spin-dried. Cy3 and Cy5 detection reagents were mixed with
the hybridisation buffer in a 25-μL reaction mix and incubated
at 80°C for 10 minutes and then at 64°C until loading onto a
pre-warmed array. After 4 hours of incubation at 64°C in a dark
humidified chamber, the slides were washed as before and
scanned on a DNA microarray scanner (G2565AA Microarray
Scanner System; Agilent Technologies, Santa Clara, CA,
USA). Each sample was hybridised to four slides (two dupli-
cates for each Cy3/Cy5 dye swap), except HB4a, for which
the dye swap was performed only once.
Microarray images were analysed by using GenePix Pro soft-
ware version 4.1 (Molecular Devices Corporation, Sunnyvale,
CA, USA), and further computational analysis of the miRNA
expression data was performed using Gene Expression Pat-
tern Analysis Suite version 2.0 [35]. Data were normalised
Figure 1
Analysis of mRNA gene expression in breast cell lines and normal tissue Analysis of mRNA gene expression in breast cell lines and normal tissue. (a) Analysis of differentially expressed mRNAs. Clustering heatmap for 
genes with analysis of variance B values of greater than 10 after either a median or a quantile normalisation. Cell type origin (B, basal; L, luminal; N, 
normal; S?, possible stem cell) and status of oestrogen receptor/progesterone receptor (ER/PR) are indicated on the left. mRNA clusters are indi-
cated by purple letters (below, with their key enriched process) and purple arrows (above and below). ECM, extracellular matrix; VR, viral response. 
(b) Analysis of luminal/basal mRNA markers. The average log2 intensity of expression of 252 luminal and 360 basal annotated non-redundant mark-
ers is shown.Available online http://breast-cancer-research.com/content/10/3/R54
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using the DNAMD (Diagnosis and Normalization for MicroAr-
ray Data) tool [36]. User-defined settings were (a) GenePix
negative-flagged spots for the print-tip loess, which were
included for intra-array normalisation but excluded from any
further analysis, and (b) a background-half correction method.
Inconsistent replicates (average distance to the median of
greater than 0.5) were removed after the normalisation step
using the Preprocessing tool [37]. Data are available on
ArrayExpress under accession number E-UCON-2 (temporary
username: Reviewer_E-UCON-2, password: 11690417121
46). Only data from miRNAs with signal intensity (A values)
greater than 6 were considered reliable and taken for further
analysis. To account for variable probe-specific dye bias, final
M values were calculated as the difference between the aver-
age log2 (ratio) values from Cy3 and Cy5 dye swaps. Differen-
tially expressed miRNAs were defined as the genes for which
at least one value was up- or down-expressed compared with
the pool with log2 greater than 2.5. M values of differentially
expressed or all miRNAs were clustered by CIMminer using
correlation distances with 'cluster method: average' [38,39].
MicroRNA profiling on Luminex bead arrays
Following the method described in [40], miRNAs were
extracted from 5 μg of total RNA using denaturing PAGE.
Samples were spiked with three synthetic pre-labelling control
RNAs (3 fmol per sample; pCAGUCAGUCAGUCAGU-
CAGUCAG, pGACCUCCAUGUAAACGUACAA, and pUU
GCAGAUAACUGGUACAAG; Dharmacon, Chicago, IL,
USA) to monitor target preparation efficiency. After purifica-
tion of the small 18- to 26-base pair RNAs, they were ligated
at the 3' and 5' end to adapters using T4 RNA ligase (3'
adapter – puuuAACCGCGAATTCCAGT; 5' adapter – ACG-
GAATTCCTCACTaaa). Bi-ligated products were reverse-
transcribed using an adaptor-specific primer (M37 – TACT-
GGAATTCGCGGTTA) and then amplified and biotin-labelled
by PCR (M37 and M33 – biotin-CAACGGAATTCCT-
CACTAAA) for 18 cycles of 95°C for 30 seconds, 50°C for 30
seconds, and 72°C for 40 seconds. PCR products were pre-
cipitated without glycogen and redissolved in 66 μL 1× TE
buffer containing 1 μL of three biotinylated post-labelling con-
trols (100 fmol each, FVR506, PTG20210, and MRC677).
Four bead sets were constructed containing 90 different
coded beads each. Altogether, they were used to profile 310
miRNAs, including all human miRNAs known at the time, six
labelling controls and six bead repeats common to all bead
sets to aid subsequent normalisation. Each labelled sample
was hybridised to the four bead sets to generate a complete
miRNA profile. Oligos were 5'-amino modified with a 6-carbon
linker and conjugated to carboxylated xMAP beads (Luminex
Corporation, Austin, TX, USA) in 96-well formats following the
standard protocol of the manufacturer. To generate bead set
pools, 3 μL of each oligo-bead conjugate was mixed into 1-mL
1.5× tetramethylammonium chloride (TMAC) buffer (Luminex
Corporation). Samples were hybridised in a 96-well format
alongside background controls, two water blanks, and at least
three bead blanks containing water instead of the labelled
sample for use as a background control. Repeat samples were
included across bead sets and sample plates. Hybridisation
was carried out overnight at 50°C with 33 μL of the bead pool
and 15 μL of labelled sample. Prior to reading on the Luminex,
unbound sample was removed from beads by washing with 1
× TE (Tris + EDTA [ethylenediaminetetraacetic acid]) and
resuspending in 1 × TMAC buffer. Streptavidin-phycoerythrin
(premium grade; Invitrogen Corporation) was added to the
beads (1:100 dilution) and incubated for 10 minutes at 50°C
to bind to biotin moieties on the cDNA. Samples were proc-
essed on a Luminex 100 machine, and median fluorescence
intensity values were measured. Data are presented in this
paper without any further manipulation.
Real-time reverse transcription-polymerase chain 
reaction analysis of microRNAs
Real-time RT-PCR (qRT-PCR) analysis of miRNAs was per-
formed essentially as previously described [41]. The small-
RNA fraction (500 ng) was polyadenylated by PAP (Ambion)
at 37°C for 1 hour in a 6-μL reaction. After phenol-chloroform
extraction and ethanol precipitation, the polyadenylated small
RNAs were reversed-transcribed according to the manufac-
turer's protocols using 200 U SuperScript-II Reverse Tran-
scriptase (Invitrogen Corporation) and 0.5-μg poly(T) adapter
(GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTT
TTTTTTVN). The small cDNAs were then treated with RNAse
H at 37°C for 1 hour and finally diluted 240-fold. Negative con-
trols were included in both PAP and RT reactions. Moreover,
two additional RT reactions were performed using half and
double the input of polyadenylated small RNAs to ensure the
linearity of the RT step. The melting temperature for each
miRNA was experimentally determined from the thermal disso-
ciation curves using ABI Prism 7900 HT (Applied Biosystems,
Foster City, CA, USA).
Finally, the real-time PCR step was carried out in triplicate at
the optimal temperature and typically contained 5 pmol of the
gene-specific primer, 5 pmol of the common antisense oligo-
nucleotide (GCGAGCACAGAATTAATACGACTC), 10 μL
SYBR Green PCR Master Mix (Applied Biosystems), and 6 μL
of the diluted cDNAs in a total volume of 20 μL. Each set of
PCRs included a dilution series of a reference cDNA to be
used for quantitation. The sequences of forward primers for
mature miRNAs were identical to the complete miRNA
sequence listed in the miRBASE database. Additional forward
primers were 5S rRNA ACCGGGTGCTGTAGGCT, Pre-mir-
127 GGTCGGAAGTCTCATC, Pre-mir-126 GCTGGCGA
CGGGACAT, Pre-mir-143 CGCCCTGTCTCCCAGCCT,
Pre-mir-145 GATGCTAAGATGGGGATTC, Pre-mir-155
TGCCTCCAACTGACTCCTAC, Pre-mir-199a-1 GTTCAG-
GAGGCTCTCAATGTG, Pre-mir-199a-2 GACTGGGCAAG
GGAGAGCA, and Pre-mir-214 GCAGAACATCCGCTCA
CC.Breast Cancer Research    Vol 10 No 3    Git et al.
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The following quality control was applied before data sets
were accepted: (a) both PAP and RT negative controls gave
negligible values or displayed dissociation curves that were
significantly different from those in experimental samples, (b)
the real-time PCR values of samples containing RT reactions
programmed with different RNA inputs showed a dose
response or at the very least no reverse response, and (c) the
linear fit of the quantitative PCR values of the dilution series
was greater than 90%. As the units describing miRNA quanti-
ties were arbitrary, data were scaled within each gene ana-
lysed so that the highest-expressing sample was set to 1 and,
unless otherwise indicated, was not further normalised.
Array comparative genomic hybridisation on bacterial 
artificial chromosome arrays
Comparative genomic hybridisation (CGH) on bacterial artifi-
cial chromosome (BAC) arrays was performed as described
[42,43], essentially according to the methods of [44] using an
in-house array [45] comprising DNA amplified from BACs 10
Mb or less apart across the whole genome spotted in triplicate
onto amine-binding slides (CodeLink Activated Slides; Amer-
sham Biosciences, now part of GE Healthcare) using a Micro-
Grid II arrayer (BioRobotics, Boston, MA, USA).
Labelling and hybridisation protocols were as described in
[44] with slight modifications. Pre-hybridisation and hybridisa-
tion volumes were scaled down for an array surface of 2 × 2
cm delimited by an adhesive plastic frame and performed in
humid hybridisation chambers (Camlab Limited, Cambridge,
UK). Slides were washed in PBS/0.05% Tween-20 for 10
minutes at room temperature before and after a main wash in
50% formamide/0.5 × SSC for 30 minutes at 42°C.
Arrays were scanned using an Axon Genepix 4100 and the
data were acquired using Genepix4.1 software (Molecular
Devices Corporation) to perform segmentation and calculate
intensities after background subtraction. Spots with intensity
below twice the median intensity of the Drosophila clones
were rejected. Test/reference ratios were then calculated and
normalised to the median ratio of the autosomal chromosome
clones. Spots with ratios more than 10% different from the
median of the triplicate were rejected. If a minimum of two
spots of the triplicate were accepted, the mean of the log2
ratios was calculated. For ease of annotation, data points dif-
fering from the normal reference sample with a log2 ratio of
greater than 0.2 or less than -0.2 were considered gains or
losses, respectively.
Array comparative genomic hybridisation on 
oligonucleotide arrays
DNA was extracted from cell lines using a standard SDS/Pro-
teinase K method, quantified with a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies, Wilmington, DE,
USA), and labelled using the BioPrime DNA labelling system
(Invitrogen Corporation). Labelled DNA was hybridised as
described previously [46] to oligonucleotide arrays containing
60-mer oligonucleotides representing 28,830 unique genes
as designed by Compugen (San Jose, CA, USA). The array
construction has been described previously [46], and the
complete data and analysis have been reported elsewhere
[47].
Fluorescence ratios of scanned images of arrays were
obtained using Bluefuse version 3.2 (BlueGnome, Cambridge,
UK). After mapping to Human Mar. 2006 assembly (hg18),
27,801 unique positions were identified. The log2 ratios were
then normalised to their mode values by using the R/Biocon-
ductor package limma  [48]. For ease of annotation, data
points differing from the normal reference sample with a log2
ratio of greater than 0.5 or less than -0.5 were considered
gains or losses, respectively.
Consent and licenses
All research was carried out in compliance with ethics guide-
lines and regulations. Human B cells were purified from waste
products of blood donations with approval from the Adden-
brookes Hospital Local Research Ethics Committee.
Results
mRNA expression profiling and gene ontology analysis
First, we compared the mRNA expression profile of PMC42
with a panel of commonly used breast cancer cell lines as well
as immortalised normal breast epithelium. One thousand nine
hundred forty-three genes with significantly differential expres-
sion were used for unsupervised clustering (Figure 1a). We
observed that the resulting tree was largely in agreement with
the founding cell type and not the ER/PR status. The primary
separation was between normal breast tissue (NormalA and
NormalS) and cell lines. This most likely represents the mixed
population of cells (for example, epithelial, stromal, and inflam-
matory) contained within the Normal samples (see below).
Importantly, the readings of the epithelial genes were of similar
intensities in the Normal and cell line samples, showing that
the mixed nature of the Normal sample does not preclude it as
a reference. Amongst the cell lines, PMC42 clustered with
HB4a. The other four breast cancer cell lines were clustered
together, with the luminal lines on one branch and BT20, a
basal breast cancer line, on another (classification based on
[30] and references therein). HCC1419 and MDAMB361
were particularly similar despite their opposite ER/PR status.
MT3, a colon cell line, clustered with the non-PMC42 breast
cancer cell lines.
We then examined the gene ontology terms enriched in the
mRNAs clusters underscoring the relationships between the
samples (A-F in Figure 1a). Cluster E spanned 244 genes
overexpressed in all cell lines compared with normal tissue
and contained a high proportion of genes related to cell divi-
sion and DNA repair (approximately 35% of the genes; P val-
ues down to 2.94 × 10-18), reflecting the high rate of cell cycleAvailable online http://breast-cancer-research.com/content/10/3/R54
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of immortalised cell lines. Cluster B (underexpressed in all cell
lines compared with normal tissue) contained 479 genes with
enrichment in muscle-related functions (approximately 25% of
the genes; P values down to 5.10 × 10-4) and genes involved
in immune or inflammatory response (approximately 20% of
the genes; P values down to 4.37 × 10-5). Both of these gene
classes probably originate from the non-epithelial components
of breast tissue which are absent in the cell lines. Genes
related to viral response were also noted in cluster A, spanning
61 genes that were high in both normal tissue and the cell line
derivative of normal breast epithelium (HB4a) compared with
cancer cell lines (P values down to 7.35 × 10-5). Interestingly,
HB4a also expresses high levels of the interferon-response
gene cluster [49].
Of particular interest was cluster C, spanning 462 genes that
were high in normal tissue, immortalised breast epithelium,
and PMC42. This cluster was rich in genes related to ECM,
including basement membrane (BM) (17% of the genes; P val-
ues down to 5.48 × 10-4). Jongeneel and colleagues [50] have
reported that HB4a abundantly expressed components of the
ECM. Recent views attributing cell-cell and cell-ECM interac-
tions with a major role in the suppression of breast neoplasia
([3] and references therein) propose a significant biological
context for this gene cluster. Moreover, it has been demon-
strated that micro-environmental signals can override genetic
infidelity [51,52]. When clustering was performed excluding
HB4a, the mRNA cluster overexpressed in normal and
PMC42 samples also contained genes related to fat metabo-
lism, reflecting the milk-producing nature of these cells (data
not shown). No significantly enriched gene ontology terms
were found in cluster F (481 genes that were highly expressed
in all cell lines except PMC42 and HB4a) or D (116 genes
highly expressed in the colon line MT3). A full listing of ontol-
ogy terms and the corresponding genes identified by FatiGO
is available as Supplementary file 1.
We then tested whether the segregation of PMC42 from the
other breast cancer cell lines merely reflects a difference in
their luminal/basal nature. Recent attempts to pinpoint the
gene expression signature underlying the classification of
breast samples [for example, [30,49,53,54]] revealed gene
sets that primarily divide breast samples into two main catego-
ries, the luminal and the non-luminal, each of which can be
subsequently subdivided into finer groups. We therefore
examined the expression of several such gene sets in our sam-
ples. Figure 1b shows the average log2 expression values for
luminal and basal markers, as well as overall intensities of gene
expression, of a classifying gene set identified in breast cell
lines [30]. While the overall signal intensity on the arrays was
similar, the intensities of the luminal/basal markers offered a
clear separation of breast samples into luminal and non-lumi-
nal groups. The former, showing a high expression of luminal
markers and a low expression of basal markers, contained cell
lines arising from luminal progenitors (namely, MDAMB361,
MCF7, and HCC1419) ([30] and references therein). The
non-luminal group, showing lower levels of luminal markers
and high levels of basal markers, encompassed the previously
clustered normal breast tissue, HB4a and PMC42, but also
BT20 (a known basal cell line, confirmed by cytokeratin 5/6
immunostaining; data not shown). Therefore, the overall clus-
tering of PMC42 and HB4a with normal breast tissue was not
due solely to the basal nature of these cell lines since BT20, a
known basal cell line, unequivocally clustered with the luminal
cell lines (Figure 1a). MT3, a colorectal cancer cell line,
showed low levels of both types of markers.
Comparison of the mRNA profiles to the gene expression clas-
sifiers described for breast tumours [54] consistently identi-
fied the normal breast samples as Class-Normal, MDAMB361
and HCC1419 as Luminal type A, and MCF7 as Luminal type
B. BT20, PMC42, and HB4a clustered with the Basal and
Her2 classifiers but their precise hierarchy varied depending
on the algorithm employed (data not shown). PMC42 and
HB4a also expressed many genes (notably, many collagen iso-
forms) attributed to the claudin-low mesenchymal/stromal/
fibroblast tumour subtype [49,53], but the importance of this
classification in the context of cell lines awaits further
investigation.
MicroRNA expression profiling
Using an in-house array, we examined the expression of 171
miRNAs with a pooled cancer cell line RNA sample as refer-
ence. Clustering analysis of the 129 miRNAs with reliable
readings was performed using several algorithms. A typical
outcome is presented in Figure 2a. The main feature consist-
ent with all algorithms used was the separation of normal
breast tissue and PMC42 from all other cell lines. Importantly,
the separation of PMC42 from other cell lines held true even
when the normal sample was omitted from the analysis (data
not shown), suggesting that its profile is inherently different
and its separation is not driven by a minor similarity to the
vastly different normal sample. On the other branch, the clus-
tering did not partition according to tissue type (colon versus
breast), progenitor type (normal versus cancer), ER/PR status,
or luminal/basal nature of the cell, regardless of the algorithm
employed. This was strikingly emphasised by MT3, an ER/PR-
negative colon cancer cell line, sharing a branch with HB4a,
an ER/PR-positive immortalised breast luminal epithelium line.
It is also noteworthy that, although the mRNA expression of
HCC1419 was closest to MDAMB361, its miRNA profile was
most similar to that of MCF7, suggesting that the two profiles
are not co-regulated.
Clustering analysis of the 50 differentially expressed miRNAs
(defined in Materials and methods) showed two main
branches spanning miRNAs that were either lost (16 miRNAs)
or overexpressed (34 miRNA) in non-PMC42 cell lines com-
pared with normal and PMC42 (Figure 2b, upper). The most
striking cluster contained 14 miRNAs that were essentiallyBreast Cancer Research    Vol 10 No 3    Git et al.
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only expressed in PMC42 and normal breast tissue (enlarged
excerpt in Figure 2b). In contrast, miRNAs overexpressed in
cell lines in comparison with normal/PMC42 seemed to be
less consistent, only overexpressed in some of the non-
PMC42 cell lines.
Examination of the miRNAs specifically expressed in PMC42
and Normal breast tissue (hereafter termed PN miRNA cluster)
revealed many miRNAs repeatedly reported to be lost in
tumours and cancer cell lines. These include miR-127 (for
example, [55-57]), miR-199a sense and antisense (for exam-
ple, [56-59]), and miRNAs 143 and 145 (for example, [56,58-
62]). Importantly, PN miRNAs often show a correlated expres-
sion, most notably appearing as a near-continuous cluster dif-
ferentiating between neoplastic and non-neoplastic samples
in the prostate [56] and ovary [59]. Similarly, they are found to
differentiate low-grade, normal-like, and luminal A breast
tumours from the more aggressive breast cancer cases (high-
grade, Her2, basal, and Luminal B) [63].
Validation of expression of selected microRNA
We validated the differential expression of the PN miRNAs by
two independent methods for miRNA quantitation: single-
channel Luminex bead arrays and real-time RT-PCR. Figure 3
summarises the results obtained from all three methods for 26
miRNAs, including 11 PN miRNAs as well as 15 non-PN con-
trol miRNAs with varying expression profiles. The alternative
methods confirmed the specific loss of PN miRNAs, but not
control miRNAs, from the non-PMC42 samples. The overall
correlations between the methods were qRT-PCR/bead
arrays 62%, qRT-PCR/slide arrays 65%, and bead arrays/
slide arrays 43%. miRNAs 22 and 182 had at least one nega-
tive pair-wise correlation between the methods, and miR-126
appears to be expressed only in normal tissue, and these miR-
NAs were subsequently not considered as part of the PN
cluster.
The limited correlation observed between the three platforms
is the result of both conceptual and technical differences. For
example, the initial choice of input RNA (total RNA, small-RNA
fractions, and gel-purified mature miRNAs) is, in essence, a
'biological normalisation' step assuming that the rRNA or
tRNA levels remain unchanged. We found inherent differ-
ences in the tRNA/rRNA ratio in different samples (7% to
20%), raising doubts as to the validity of either as a reference
point. The extent of sample skewing during labelling by
sequence-specific bias of RNA ligase [64] or PCR amplifica-
tion is at present unknown. In addition, both array-based tech-
nologies necessitate a compromise in hybridisation conditions
due to the range of miRNA melting temperatures. Most
acutely, a low hybridisation temperature makes the distinction
between miRNA family members (which differ by one to three
nucleotides) very unreliable, thus presenting miRNA
expression level readings that have contributions from several
family members depending on their abundance and cross-
reactivity in each assay. Further complexity in the interpretation
Figure 2
Analysis of microRNA (miRNA) gene expression in breast cancer cell lines and normal tissue Analysis of microRNA (miRNA) gene expression in breast cancer cell lines and normal tissue. (a) Global miRNA heatmap. Log2 ratios of spots with 
intensity (A values) greater than 6 were used in CIMminer clustering analysis using correlation distances. (b) Heatmap of differentially expressed 
miRNAs. miRNA genes for which at least one value differed with log2 greater than 2.5 from the pool (either upregulated or downregulated) were 
used in CIMminer clustering analysis using correlation distance (upper). The PN miRNA cluster is indicated by a star and is enlarged (lower). The cell 
type origin (B, basal; L, luminal; N, normal; S?, possible stem cell) and the status of oestrogen receptor/progesterone receptor (ER/PR) are indi-
cated on the left. PN miRNA, microRNA specifically expressed in PMC42 and Normal breast tissue.Available online http://breast-cancer-research.com/content/10/3/R54
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of hybridisation signals arises from potential contributions of
unprocessed precursor miRNAs where input samples have
not been size-selected using PAGE. Lastly, as computational
normalisation of miRNA expression data as yet awaits a golden
standard, we analysed all our data in non-normalised mode or
normalised to either 5S rRNA or the GEOmean of miRNAs 93
and 191, recently proposed as the most stable small-RNA ref-
erence [65]. Importantly, the differences in PN miRNA expres-
sion are specific and consistent, and the differences in PN
miRNA levels are significantly larger than can be attributed to
any of the aforementioned factors.
Confirmation of PN microRNA loss in additional breast 
and lymphoblastoid cell lines
To confirm the uniqueness of PMC42 in maintaining the
expression of PN miRNAs, we examined the expression of
selected PN and control miRNAs in 13 additional breast cell
lines (2 immortalised normal epithelia and 11 from cancerous
origin). Figure 4a summarises the obtained data, normalised to
the GEOmean of miRNAs 93 and 191 [65]. The expression of
miRNAs 214, 143, 145, and both 199a derivatives was com-
pletely lost in all examined cell lines except PMC42. The
reduction in expression of miR-127 in the same samples was
less prominent but still significant.
As the downregulation of many of the PN miRNAs has been
reported in non-breast solid tumours and derived cell lines
(such as ovary [59], pancreas [66], liver [58], colon
[57,60,67,68], lung [62], and prostate [56]), we also exam-
ined the levels of the 26 miRNAs in CD19+ B cells from three
healthy blood donors and in three immortalised lymphoblast-
oid cell lines (Figure 4b). To ensure that no excessive RNA
degradation occurred as a result of the inevitable delay in RNA
extraction from normal bloods, small-RNA fractions were visu-
alised following high-resolution electrophoresis, and no differ-
ences were discernible in the quantity, quality, or relative
content of RNA derived from CD19+ healthy B cells or lym-
phoblastoid cell lines (data not shown).
Apart from miR-127, which showed no difference between
normal and immortalised lymphocytes, all validated PN miR-
NAs were downregulated in the lymphoblastoid cell lines, con-
firming the ubiquity of the PN expression profile. Loss of PN
miRNAs in lymphoblastoid cell lines was specific as other miR-
NAs showed similar (or even increased) expression in the
same samples. miR-214 was undetectable in any lymphocyte-
derived samples, consistent with its reported low expression in
lymph nodes and high expression in breast [69]. Conversely,
the high levels of miR-126 measured in normal lymphocytes
might account for its high expression in normal breast tissue
despite its low levels in breast epithelial cell lines.
Figure 3
Validation of microRNA (miRNA) expression by Luminex bead arrays and real-time quantitative reverse transcription-polymerase chain reaction (qRT- PCR) Validation of microRNA (miRNA) expression by Luminex bead arrays and real-time quantitative reverse transcription-polymerase chain reaction (qRT-
PCR). The levels of 26 miRNAs measured using the methods indicated on the left are shown. qRT-PCR experiments were performed three times, 
each in triplicate, except for miRNAs 7, 126, and 126* (red diamond), which were measured once in triplicate; error bars indicate one standard devi-
ation. On Luminex bead arrays, miRNAs 127 and 17-3p were below detection (red star). As units of expression in all methods are arbitrary, data 
were scaled to the highest-expressing sample for each miRNA. Normalised slide microarray data are presented on a non-logarithmic scale identical 
to the other two methods, for which the data were not normalised in any way. PN miRNAs appear in boldface. miRNAs with at least one negative 
value for correlation between the methods are shown in red. PN miRNA, microRNA specifically expressed in PMC42 and Normal breast tissue.Breast Cancer Research    Vol 10 No 3    Git et al.
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Investigation of the mechanism of PN microRNA loss of 
expression
We then examined the potential mechanisms underlying the
loss of PN miRNAs in non-PMC42 cell lines. For this analysis,
we focused on the miRNAs that showed consistent results
with the three independent methods (miRNAs of the 127, 143,
145, 199, and 214 families). As the karyotype of many cell
lines is highly rearranged, we examined whether the loss of
expression of the PN miRNAs in the five non-PMC42 cell lines
can be attributed to losses of the corresponding genomic
areas or parallel gains in PMC42. To this end, we analysed
CGH (array CGH) data obtained from two types of arrays: oli-
gonucleotide arrays (offering a better resolution), which were
used to probe the copy number of chromosomal regions
immediately adjacent to the miRNA of interest, and BAC
arrays, which provided information about gene-poor genomic
regions albeit with lower resolution (tiling BAC arrays were not
available for our genomic areas of interest). The results of both
are summarised in Figure 5a. Not only did we not find any
consistent losses in areas adjoining PN miRNAs in non-
PMC42 cell lines, some of them were in fact amplified in non-
expressing cell lines (for example, chromosome 1 in BT20).
Therefore, although some genomic losses (for example, chro-
mosome 1 in MDAMB361) or breakpoints (for example, chro-
mosome 14 in MCF7) may contribute to PN miRNA
downregulation and specific micro-deletions spanning PN
miRNAs cannot at present be eliminated, it seems unlikely that
genomic copy number alterations are the main mechanism
underlying changes in their expression.
Figure 4
Real-time reverse transcription-polymerase chain reaction validation of PN miRNA loss in breast and lymphoblastoid (LB) cell lines Real-time reverse transcription-polymerase chain reaction validation of PN miRNA loss in breast and lymphoblastoid (LB) cell lines. (a) Expression of 
the listed miRNA genes in 11 additional breast cancer and 2 immortalised normal cell lines alongside 6 of the initial panel of tested cell lines (red). 
The luminal/basal nature of each cell line is indicated on the right. Values were normalised to the GEOmean of miRNAs 93 and 191 [65]. Data were 
scaled to the highest-expressing sample for each miRNA. PN miRNAs appear in boldface. (b) The expression of the listed miRNA genes in B cells 
from 3 healthy blood donors and 3 LB cell lines. Values were normalised to the levels of 5S rRNA and scaled as above. The levels of miRNAs 127, 
221, 199a-s, 199a-as, 143, and 145 were independently tested twice. PN miRNAs appear in boldface. miR-214 was below the detection threshold 
in all samples. PN miRNA, microRNA specifically expressed in PMC42 and Normal breast tissue.Available online http://breast-cancer-research.com/content/10/3/R54
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We have also examined the changes in the expression of the
mRNAs in whose introns some of the PN miRNAs reside.
These can be considered as reporters for genomic presence
and accessibility to transcriptional machinery (for instance,
due to chromatin packing). miRNA/mRNA pairs included miR-
199a-2 and miR-214 within DNM3 (opposite strands) and
miR-199a-1 within DNM2 (opposite strand). miR-127 is
located within RTL1 (retrotransposon-like-1) encoding a retro-
Figure 5
Mechanisms of PN miRNAs loss Mechanisms of PN miRNAs loss. (a) Examination of genomic copy number. Genomic copy numbers of the chromosomal regions surrounding candi-
date miRNAs from the PN cluster (grey highlight) were examined using bacterial artificial chromosome (BAC) and oligonucleotide array comparative 
genomic hybridisation and are listed by genomic location. Normalised log2 (copy numbers) of the two nearest clones on each array (names in square 
brackets) are reported unless unavailable due to the miRNA's proximity to the end of the chromosome. Gains are highlighted in orange; losses are 
highlighted in green. The mRNAs in whose introns the corresponding miRNAs reside are highlighted in yellow; where available, the log2 (mRNA 
expression) is given as measured by beadchip arrays. ND, not determined. (b) Real-time reverse transcription-polymerase chain reaction examination 
of pre-miRNA levels. As units of expression are arbitrary, data were scaled to the highest-expressing sample for each miRNA and were not otherwise 
normalised. Experiments were performed twice in triplicate; bars indicate one standard deviation. PN miRNA, microRNA specifically expressed in 
PMC42 and Normal breast tissue.Breast Cancer Research    Vol 10 No 3    Git et al.
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virus-related polyprotein for which expression data were una-
vailable. We have also included miR-199b residing within
DNM1 (opposite strands), which was omitted from the global
miRNA analysis due to low A values but whose expression
profile closely resembles that of miR-199a(s/as) (data not
shown). Illumina beadchip data for the mRNAs listed above
(Figure 5a, highlighted in yellow) show that not only is the cor-
responding genomic area not lost in either cell line, but they
are either actively transcribed with similar efficiencies in all cell
lines (basal levels of DNM3 consistent with its tissue-
restricted expression; high expression of the ubiquitous
DNM2; [70] and references therein) or even overexpressed in
BT20 and MDAMB361 (EGFL7), suggesting that it is not
chromatin accessibility that renders the PN miRNA genes
inactive in non-PMC42 cell lines.
Last, using real-time RT-PCR, we examined the levels of the
precursors of the PN miRNAs in the same samples so that the
data in Figure 5b and Figure 3 (top panel) are directly compa-
rable. The regulation of miRNAs 143 and 145 is at least par-
tially achieved at the level of their precursors. In contrast, the
precursor for miR-127 appears to be ubiquitously expressed
in all cell lines and both precursors for miR-199a are present
in many of the cell lines (though at lower levels in BT20)
despite their corresponding mature products being preferen-
tially formed or retained by normal and PMC42 cells only.
Post-transcriptional mechanisms may be essential for the loss
of miRNAs arising from multiple genomic loci, such as miR-
199a-1 and miR-199a-2. Overall, it appears that the expres-
sion of the PN miRNAs is governed at more than one level with
combinations of genomic, transcriptional, and post-transcrip-
tional/processing mechanisms contributing to the loss of their
mature form in non-PMC42 cell lines.
Discussion
PMC42 has normal-like mRNA and microRNA profiles
We show that PMC42, HB4a, and normal breast tissue have
comparable mRNA profiles. The major feature segregating
them from non-PMC42 cancer lines is high levels of mRNAs
encoding hallmark components of the BM, such as collagen
(various collagens, including type IV, preferred by mammary
epithelium [4]), fibronectin (FN1), and laminins (subunits α1,
α4, β1, and γ1). The latter are of great importance in the pres-
ervation of normal breast phenotype as modulators of both the
proliferative response to stimulators like oestrogen [71] and of
cell ability to induce β-casein [72]. ECM-related genes, and in
particular laminins, were also reported to be perturbed in
malignant breast epithelial cells compared with primary cul-
tures of normal breast epithelium in a transcriptome analysis
across several platforms [73]. PMC42 also exhibits markers of
unregulated cell division emblematic of all cell lines. This was
exemplified by its overexpression of 'breast cancer prolifera-
tion signatures', including BUB1, Polo-like kinase, and
numerous cyclins, which are also upregulated in tumours com-
pared with primary normal epithelium ([73] and references
therein).
We also show that PMC42, but not any other cell line includ-
ing several immortalised normal epithelial cell lines (HB4a,
HMT3522, and MCF10A), possesses a normal-like miRNA
profile. PMC42 is, to the best of our knowledge, the first breast
cell line described to bear such a gene expression signature.
We note the discrepancy between the normal-like mRNA and
the heavily disrupted miRNA profiles of the immortalised nor-
mal epithelial lines, further underscoring the uniqueness of
PMC42 as a model system. We focus on a group of miRNAs,
whose increased expression in normal breast and PMC42 was
ascertained using three independent methods and whose
clustering is not algorithm-dependent. These PN miRNAs
(miRNAs of the 127, 143, 145, 199, and 214 families) are
almost ubiquitously associated with normal tissue, are absent
in the brain [74], and are lost in the process of cell line estab-
lishment, as demonstrated here for breast and B cells and
reported for many other tissues listed above. Interestingly, we
were unable to detect miR-214 in B cells, suggesting that the
expression, regulation, and possibly tropism of miR-214 is tis-
sue-specific. Indeed, there are few reports of cancer-related
loss of miR-214, and it has even been reported upregulated in
lung tumours [62] alongside strongly downregulated miRNAs
of the 143, 145, and 199 families. As it appears that tissue-
specific signatures of miRNAs are of a combinatorial nature,
miRNAs that are abundant in breast (199 and 214 families
[69]) could potentially contribute to tissue-specific gene regu-
lation as well as to more ubiquitous normal tissue
homeostasis.
Function and regulation of PN microRNAs
Although their native targets and phenotypic effects await
detailed molecular investigation, some insights into the
biological activity of PN miRNAs have been emerging recently.
miRNA-214 has been assigned two roles: in HeLa cells it is
required for apoptosis [75] while in zebrafish development it is
involved in the specification of muscle cell fate [76], presuma-
bly representing one of its tissue-specific roles. In parallel, two
independent papers demonstrated that the reintroduction of
miRNAs 143 and 145 into cancer cell lines inhibits their
growth [40,61], the latter also identifying ERK5 as a target of
miR-143. A possible effector of miR-127 was identified as the
proto-oncogene BCL6, a key player in B-cell apoptosis and
neoplasia [55]. The reported pro-apoptotic and anti-prolifera-
tive activities of the PN miRNAs suggest that their loss in cell
lines and tumours is not a coincidental or fortuitous observa-
tion but rather earmarks their role in normal cell fate. Moreover,
it has been postulated that, rather than directly initiate devel-
opmental pathways, miRNAs canalise these events, confer
robustness to otherwise-stochastic processes, and buffer
genetic noise [77]. Presumably, their loss is imperative for
concomitant perturbations in multiple molecular pathways typ-
ical of neoplastic transformation. The study of PN miRNAs soAvailable online http://breast-cancer-research.com/content/10/3/R54
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far has been significantly compromised by their loss from the
cell line model systems best suited for their study, further
underscoring the utility of PMC42 in future research.
Little is known about the regulation of the multi-step process
leading to the formation of a mature miRNA including the
genes' epigenetic modifications, transcriptional control, and
the Drosha and Dicer processing of the resulting RNA. In our
study, we have shown that no single mechanism accounts for
the loss of the PN miRNAs in non-PMC42 cell lines. This find-
ing is congruent with attempts to delineate the regulation of
mature miRNA expression in other systems. At the epigenetic
level, a combination of DNA demethylation and histone
deacetylase inhibition can induce the expression of miR-127 in
some, but not all, cancer cell lines without a parallel upregula-
tion for other miRNAs at the same genomic location [55]. Anal-
ysis of several miRNA primary transcripts and their mature
counterparts in a teratocarcinoma cell line and in mouse
embryogenesis shows a discrepancy between the two expres-
sion profiles, indicating that many miRNAs are subject to post-
transcriptional regulation [78]. However, similarly to our
results, the levels of mature miRNAs 143 and 145 appeared
to mirror those of their single primary transcript, suggesting
that these miRNAs either uniquely escape regulation at the
processing steps or are otherwise also fortuitously transcrip-
tionally regulated in a similar way. Fittingly, correct processing
of exogenous pre-miRNAs 143 and 145 in cell lines that do
not express mature miR-143/145 was reported [60].
Interestingly, reduced mature, but not precursor, miR-143 and
miR-145 in cancer cell lines have been previously noted, sug-
gesting that their processing can also be regulated and high-
lighting the multilevel regulation of these miRNAs [67].
A cell line model for normal breast epithelium
Studies of normal breast epithelium have been limited to pri-
mary cultures and handicapped by aspects of their purification
and handling, such as finite life span and limiting quantity. Fur-
thermore, each primary culture is unique, making any direct
comparisons between data obtained by different laboratories
difficult. Alternatively, immortalised normal cell lines can be
used. However, concern was voiced about the little-studied
effects of immortalisation on cellular functions either through
direct effects (for example, the effect of HPV16-E6/E7 on p53
and retinoblastoma protein [79]) or through the extensive kary-
otype rearrangements visible in HB4a [24]. Indeed, the miRNA
profile of HB4a is quite different from that of normal breast
despite similarities in their mRNA profiles.
In this study, we show that the gene expression profile defining
normal breast tissue is shared by PMC42. Despite the inher-
ent limitations of all cell lines, PMC42 satisfies many of the fea-
tures of a normal breast epithelium model. Its differentiation
provides in a single sustainable culture both epithelial and
myoepithelial cells supported by autonomous synthesis of BM
components. The coexistence of near-normal repertoires of
the regulatory miRNAs and their cognate targets is of great
value to further studies of both mRNA and miRNA pathways,
although further experiments are required to elucidate whether
this coexistence is fortuitous or whether it mirrors the regula-
tory mechanisms governing the mRNA and miRNA profiles in
normal breast epithelium.
Lastly, PN miRNAs potentially play a role in maintaining 'nor-
mal' cell proliferation or mortality. PMC42 was established
from a presumed breast progenitor cell. It is tempting to pos-
tulate that stem or progenitor cells possess natural mecha-
nisms that moderate the function of PN miRNAs and allow
self-renewal and immortality in the absence of malignant trans-
formation. Such cells would thus require fewer changes in the
process of cell line establishment and could potentially main-
tain a more normal-like gene expression signature, including
PN miRNAs. The confirmation of this hypothesis awaits further
experiments.
Conclusion
PMC42 is an unusual breast cancer cell line in its similarity to
normal breast epithelium in cell composition and physiological
responses. We present evidence that PMC42 also exhibits an
mRNA and miRNA profile highly similar to the normal breast,
including mRNAs encoding components of the BM and a
group of miRNAs that are key candidates to have tumour-sup-
pressor-like roles. Hence, PMC42 represents a unique biolog-
ical tool to gain insight into the molecular events underlying
epithelial/myoepithelial differentiation and the links between
ECM, mRNA, and miRNA expression.
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